Get the Stockscreener App
1.335
0.38%
0.015
Maxcyte Inc stock is traded at $1.335, with a volume of 534.71K.
It is up +0.38% in the last 24 hours and up +6.85% over the past month.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
See More
Previous Close:
$1.32
Open:
$1.32
24h Volume:
534.71K
Relative Volume:
0.41
Market Cap:
$137.78M
Revenue:
$32.29M
Net Income/Loss:
$-39.12M
P/E Ratio:
-3.6386
EPS:
-0.3669
Net Cash Flow:
$-29.51M
1W Performance:
+9.50%
1M Performance:
+6.85%
6M Performance:
+89.26%
1Y Performance:
-2.57%
1-Day Range:
$1.295
$1.39
1-Week Range:
$1.16
$1.54
52-Week Range:
$0.6434
$1.865
Maxcyte Inc Stock (MXCT) Company Profile
Name
Maxcyte Inc
Sector
Industry
Phone
301-517-5556
Address
9713 KEY WEST AVENUE,, ROCKVILLE
Compare MXCT vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
1.335 | 136.23M | 32.29M | -39.12M | -29.51M | -0.3669 |
ABT
Abbott Laboratories
|
110.08 | 192.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
332.38 | 130.11B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
90.66 | 116.83B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
51.55 | 75.11B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
90.78 | 52.80B | 6.30B | 1.07B | 1.09B | 1.8406 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-11-25 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-07-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-22-25 | Initiated | Stephens | Overweight |
| Nov-29-23 | Initiated | Craig Hallum | Buy |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-24-21 | Initiated | BTIG Research | Buy |
| Aug-24-21 | Initiated | Cowen | Outperform |
| Aug-24-21 | Initiated | Stephens | Overweight |
| Aug-24-21 | Initiated | Stifel | Buy |
| Aug-24-21 | Initiated | Wedbush | Outperform |
| Aug-24-21 | Initiated | William Blair | Outperform |
View All
Maxcyte Inc Stock (MXCT) Latest News
Teleconferência de Resultados do 2T26 da MaxCyte (MXCT): Guidance Reafirmado com a Expansão da Parceria com a Genentech - TradingKey
MaxCyte Inc (NASDAQ: MXCT) Stock Price, News & Analysis - Kalkine
Conferencia de resultados del T2 de 2026 de MaxCyte (MXCT): Se reafirman las proyecciones a medida que se amplía la alianza con Genentech - TradingKey
MaxCyte (MXCT) Q2 2026 Earnings Call: Guidance Reaffirmed as Genentech Partnership Expands - TradingKey
MaxCyte (MXCT) Stock Price Reflects Faith In Royalties Over Core Weakness - Sahm
TD Cowen Maintains MaxCyte(MXCT.US) With Buy Rating - Moomoo
MaxCyte revenue down 15% to USD 7.3M in Q2 2026 - Medical Buyer
MaxCyte, Inc. $MXCT Shares Acquired by Renaissance Technologies LLC - MarketBeat
Price to sales forward of MaxCyte, Inc. – MUN:MYE0 - TradingView
MaxCyte Inc (MXCT) (Q2 2026) Earnings Call Highlights: Strategic Pivot to Enterprise ... - Yahoo! Finance Canada
MXCT Looks 49.6% Undervalued on GF Value™ - GuruFocus
MaxCyte, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
MaxCyte Q2 Earnings Call Highlights - MarketBeat
MaxCyte (NASDAQ:MXCT) Issues Earnings Results - MarketBeat
MaxCyte affirms FY26 sales guidance of $30M-$32M vs estimate - scanx.trade
MaxCyte, Inc. (MXCT) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Earnings call transcript: MaxCyte tops Q2 2026 revenue forecast, shares fall - Investing.com
MaxCyte Reports Q2 Results, Highlights Genentech Partnership - TipRanks
MaxCyte Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Maxcyte, Inc. Provides Earnings Guidance for the Back Half of 2026 and Reiterates Earnings Revenue Guidance for the Full Year 2026 - marketscreener.com
Tranche Update on MaxCyte, Inc.'s Equity Buyback Plan announced on May 12, 2026. - marketscreener.com
MaxCyte Reports Second Quarter 2026 Financial Results - The Manila Times
RIVER GLOBAL INVESTORS LLP Trims MaxCyte Inc (MXCT) Stake -- Shares Trade at 52% Discount to GF Value - GuruFocus
MaxCyte Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
MaxCyte (MXCT) Q1 2026 Earnings: Narrower Loss Beats Estimates as Shares Rise 6.31%Financial Summary - dars.gov.et
Earnings Preview: MaxCyte to Report Financial Results Post-market on August 12 - Moomoo
MaxCyte | 4: Statement of changes in beneficial ownership of securities-Director Johnston John Joseph - Moomoo
Latest MXCT ETF News Today | Earnings, Events & Price Alerts - Intellectia AI
MaxCyte (MXCT) Expected to Post Earnings on Wednesday - MarketBeat
River Global Investors Discloses Investment at MaxCyte with 0.78% Stake - TradingView
MaxCyte, Inc. (MXCT) holder River Global shifts 4.3% voting stake - Stock Titan
MaxCyte Inc (MXCT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BlackRock (MXCT holder) discloses 1,402,591 MaxCyte shares, a 1.3% ownership stake - Stock Titan
MaxCyte Inc (MXCT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
MaxCyte Inc (MXCT) Institutional Confidence - TradingKey
MaxCyte Inc (MXCT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
MXCT|MaxCyte Inc|Price:1.050| - TradingKey
MXCT|MaxCyte Inc|Price:1.310|Chg%:-0.080 - TradingKey
MaxCyte Inc (MXCT) Cash Flow - TradingKey
MXCT|MaxCyte Inc|Price:1.080|Chg%:-0.040 - TradingKey
MaxCyte Inc (MXCT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
MaxCyte, Inc. Revenue Breakdown – DUS:MYE0 - TradingView
MaxCyte Inc (MXCT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Brooklands Fund Management Ltd Invests $1.54 Million in MaxCyte, Inc. $MXCT - MarketBeat
Stifel Maintains MaxCyte(MXCT.US) With Buy Rating, Maintains Target Price $4 - Moomoo
MaxCyte stock surges on Genentech technology license deal By Investing.com - Investing.com South Africa
MaxCyte stock surges on Genentech technology license deal - Investing.com
MaxCyte Enters Technology License Partnership With Genentech - marketscreener.com
Genentech licenses MaxCyte cell engineering technology - Investing.com
MaxCyte licenses cell therapy tech to Genentech for research and manufacturing support - Pluang
Genentech licenses MaxCyte cell engineering technology By Investing.com - Investing.com Canada
Maxcyte Inc Stock (MXCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):